There is no single ibogaine success rate. Numbers ranging from 30% to 88% appear in different studies — all technically accurate, none of them complete. What they measure differs: short-term withdrawal reduction, one-month symptom scores, long-term abstinence. The population differs. The conditions differ. And the role of what happens after the ceremony — which the numbers rarely capture — differs most of all. What the research actually shows, condition by condition, is below.
Ibogaine success rates vary by condition and follow-up period. For opioid use disorder: 80% of participants in published observational research reported significant withdrawal reduction at time of treatment; 30% reported sustained abstinence at long-term follow-up. For PTSD and depression: the 2023 Stanford study of 30 treatment-resistant veterans found average reductions of 88% in PTSD symptoms, 87% in depression, and 81% in anxiety at one month post-treatment.
What "Success Rate" Actually Means for Ibogaine
The question sounds simple. It is not.
"Success" for someone in opioid withdrawal means something different from "success" for a combat veteran with treatment-resistant PTSD. Abstinence at six months is a different measurement from symptom scores at 30 days. A phone survey captures different information than a validated clinical assessment tool like the PCL-5.
Most ibogaine research is observational. Participants are not randomly assigned to treatment and control conditions. There are no placebo arms — meaningful for a 12–24 hour experience that is effectively impossible to blind. The studies that exist are mostly self-reported, with short follow-up periods and small sample sizes. These are genuine methodological limitations, not reasons to dismiss the findings.
The evidence is consistent in direction. Across different research teams, different populations, and different measurement approaches, the finding repeats: ibogaine produces substantial reductions in withdrawal symptoms, craving, and psychological distress that persist beyond the acute pharmacological window. That does not happen with compounds that produce only immediate or symptomatic effects.
The numbers below come from published peer-reviewed research. They describe specific populations over specific timeframes. They do not transfer automatically to every person who seeks this work. Whether they apply to you depends on a screening process, not on identifying with the population studied.
What the Research Shows for Opioid Addiction
The most cited figures in ibogaine success rate discussions come from a 2018 observational study of subjective ibogaine effectiveness in people with problematic opioid use who had received ibogaine treatment and were surveyed afterward:
- 80% reported that ibogaine significantly reduced or eliminated withdrawal symptoms at the time of treatment
- 50% reported reduced opioid craving at the time of follow-up survey
- 25% reported that the craving reduction lasted at least three months
- 30% reported never using opioids again following treatment
- 41% reported sustained abstinence lasting more than six months at time of survey
A separate 12-month observational study published in 2017 found that 75% of participants remained abstinent from opioids for the full year following a single ibogaine treatment — a smaller study, but with a more structured follow-up protocol. A MAPS-funded study found that 40% of participants achieved "favorable outcomes," defined as maintaining at least a 75% reduction in addiction severity for 9–12 months.
For comparison: standard medication-assisted treatment produces one-year retention rates of approximately 40–60%, with significant relapse rates after discontinuation. The ibogaine numbers, while from weaker study designs, are in a comparable range — from a single intervention rather than an ongoing medication requiring continuous administration.
The Johns Hopkins School of Medicine documented that 80% of 88 participants showed either a drastic reduction or complete elimination of opioid withdrawal symptoms following ibogaine treatment. This short-term effect on withdrawal is the most consistent finding across all opioid-specific studies — more consistent than the abstinence figures, which depend heavily on what follows the ceremony.
What the Stanford Study Found for PTSD and Depression
In February 2023, a team at Stanford published findings in Nature Medicine that changed the conversation. Thirty special operations veterans — people with treatment-resistant PTSD, traumatic brain injury, and depression, who had already tried conventional approaches — received a single ibogaine session in Mexico, then were assessed one month later.
The findings at one month post-treatment:
- 88% average reduction in PTSD symptoms
- 87% average reduction in depression symptoms
- 81% average reduction in anxiety symptoms
Both ibogaine and its active metabolite noribogaine had substantially cleared from the body by the one-month measurement point. These are not acute pharmacological effects. They are changes that persisted after the compounds had metabolised.
Conventional antidepressant research considers a 50% reduction in depression scores a strong response. The Stanford findings documented 87% in a population where conventional treatment had not been adequate. Special operations veterans are not a population that approaches things with low expectations.
The study has genuine limitations. 30 people is not a definitive population. There was no placebo arm — a meaningful constraint for establishing causality. The findings apply specifically to veterans with treatment-resistant conditions and traumatic brain injury. Citing these numbers without those caveats is not honest. The numbers are compelling enough to stand on their own with the caveats included.
The response to the study has been substantive. Texas subsequently committed $50 million to clinical ibogaine trials at UTMB, UTHealth Houston, Texas A&M, and Baylor University. The controlled data the field requires is being actively pursued. The Stanford findings are a beginning, not a conclusion.
Why Integration Determines the Long-Term Result
The ceremony was profound. The person left with clarity, reduced craving, and what felt like the beginning of something different. Six weeks later, they were back where they started — or worse, because the contrast between what was possible and what they'd returned to was now sharper.
This pattern is not unusual. It is what happens when people return to the same environment, relationships, and unaddressed conditions that produced the problem in the first place — without integration support in place.
Ibogaine is metabolised into noribogaine — an active compound with a half-life of 28–36 hours that remains biologically present for weeks to months after the ceremony. This metabolite sustains a neuroplasticity window: a period during which new patterns are more accessible and old patterns less entrenched. Most relapses happen within the first 60 days, when that window is still open and support has typically dissolved.
Integration support is not a bonus service. It determines whether the ceremony produces lasting change. Providers who hand people a pamphlet and wish them luck are not providing ibogaine treatment — they are providing ibogaine. The distinction matters for understanding what the published success rate numbers capture and what they miss.
The studies that report 30% long-term abstinence are describing what happens in populations with minimal structured follow-up. Studies and providers reporting higher sustained outcomes describe populations with ongoing support during the neuroplasticity window. The difference between these outcomes is not primarily in the ceremony — it is in what follows it.
The integration period at ExploreBwiti is treated as continuous with the ceremony itself, not separate from it. Integration after plant medicine covers what this process specifically involves.
Who Is Not an Appropriate Candidate
The most honest thing that can be said about ibogaine success rate data is this: it does not apply to everyone who finds it compelling.
The people for whom ibogaine produces strong results are often those who have spent years trying other approaches first — SSRIs that blunted rather than resolved, therapy that circled without landing, abstinence-based programmes that held for months and then did not. That earned scepticism — alongside the fact that other options have been exhausted — tends to produce people who are genuinely ready for what iboga shows them. The research numbers reflect this population. They do not reflect everyone who wants to try.
Absolute medical contraindications for ibogaine:
- QT prolongation or significant cardiac arrhythmia. Ibogaine prolongs the QT interval. In a person with a pre-existing cardiac condition, this can trigger ventricular arrhythmia. This is the mechanism behind the fatalities that have occurred during ibogaine treatment — concentrated almost entirely among providers who did not conduct EKG screening before ceremony. EKG before ceremony is not optional.
- Current SSRIs or SNRIs without a supervised taper. The serotonin syndrome risk is real and potentially fatal. A supervised taper — conducted with the prescribing physician — is required first. Not a few days without medication. A supervised taper. The timeline varies by drug and dose.
- Methadone without a specific supervised transition protocol. Methadone requires a medically managed reduction to a shorter-acting opioid over weeks before ceremony is possible.
- Severe liver or kidney disease. Ibogaine is metabolised hepatically. Impaired clearance amplifies both effects and adverse risks. A liver panel is required before ceremony.
- Active psychosis or schizophrenia spectrum disorder. Ibogaine can destabilise these conditions in ways that are dangerous and not reliably reversible.
- Pregnancy. Absolute contraindication. No protocol changes this.
Someone in acute psychiatric crisis — regardless of how much they want access, and regardless of how compelling the research is — is not an appropriate candidate at that moment. The experience amplifies what is present. Entering it in a state of acute instability does not produce stability.
If you are not an appropriate candidate, we will tell you directly and without softening it. The full contraindications guidecovers each of these categories in detail, including what "conditional" versus "absolute" contraindications actually mean in practice.
Is This Right for You?
The Stanford numbers are real. So are their limitations. The opioid research is consistent in direction, if not in scale or study design. The integration window is real, measurable, and determines the long-term outcome more than the ceremony itself.
Ibogaine is most relevant for people who have already tried the available conventional options and found them insufficient. It is least relevant — and least safe — for people who are arriving at it as a first step, who have contraindicated cardiac conditions or medications, or who are looking for something that will produce lasting change without sustained effort after the ceremony ends. The medicine does not accommodate that expectation. What the experience shows people is what they have been avoiding — not what they hoped to find.
If the research is relevant to your situation and you have no cardiac contraindications, start with the FAQ for the full account of what medical screening involves and who it is not appropriate for. The ceremony page describes what working with iboga at ExploreBwiti in Vancouver specifically involves. The Stanford ibogaine study covers the primary research in detail — including what the limitations mean for interpreting the numbers. When you are ready to begin a conversation about your specific situation, the application is where that starts. We respond personally to every application within 2–3 business days.
For context on where the research stands independently: the 2023 Stanford study in Nature Medicine and the peer-reviewed opioid outcomes research on PubMed are the right starting points.